- 1 Analysis of blood and nasal epithelial transcriptomes to identify
- 2 mechanisms associated with control of SARS-CoV-2 viral load in the
- 3 upper respiratory tract

12

- 5 Mahdi Moradi Marjaneh<sup>1,2,3\*</sup>, Joseph D Challenger<sup>4</sup>, Antonio Salas<sup>5,6,7</sup>, Alberto Gómez-
- 6 Carballa<sup>5,6,7</sup>, Abilash Sivananthan<sup>1</sup>, Irene Rivero-Calle<sup>6,7,8</sup>, Gema Barbeito-Castiñeiras<sup>9</sup>,
- 7 Cher Y Foo<sup>10</sup>, Yue Wu<sup>11</sup>, Felicity Liew<sup>12</sup>, Heather R Jackson<sup>1,2</sup>, Dominic Habgood-Coote<sup>1,2</sup>,
- 8 Giselle D'Souza<sup>1,2</sup>, Samuel Nichols<sup>1,2</sup>, Victoria J Wright<sup>1,2</sup>, Michael Levin<sup>1,2</sup>, Myrsini
- 9 Kaforou<sup>1,2</sup>, Ryan S Thwaites<sup>12</sup>, Lucy C Okell<sup>4</sup>, Federico Martinón-Torres<sup>6,7,8</sup>, Aubrey J
- 10 Cunnington<sup>1,2\*</sup>, on behalf of the PERFORM Consortium<sup>†</sup> and GEN-COVID Study Group
- 11 (http://gencovid.eu)
- <sup>1</sup>Section of Paediatric Infectious Disease, Department of Infectious Disease, Imperial College
- 14 London, London, UK
- <sup>2</sup>Centre for Paediatrics and Child Health, Imperial College London, London, UK
- <sup>3</sup>Section of Virology, Department of Infectious Diseases, Faculty of Medicine, Imperial
- 17 College London, London, UK
- <sup>4</sup>Medical Research Council Centre for Global Infections Disease Analysis, Department of
- 19 Infectious Disease Epidemiology, Imperial College London, London, UK
- <sup>5</sup>Unidade de Xenética, Instituto de Ciencias Forenses, Facultade de Medicina, Universidade
- 21 de Santiago de Compostela, and GenPoB Research Group, Instituto de Investigación
- 22 Sanitaria (IDIS), Hospital Clínico Universitario de Santiago (SERGAS), Galicia, Spain
- <sup>6</sup>Genetics, Vaccines and Infections Research Group (GENVIP), Instituto de Investigación
- 24 Sanitaria de Santiago, Universidade de Santiago de Compostela, Santiago de Compostela,
- 25 Galicia, Spain

<sup>7</sup>Centro de Investigación Biomédica en Red de Enfermedades Respiratorias (CIBER-ES), Madrid, Spain <sup>8</sup>Translational Pediatrics and Infectious Diseases, Department of Pediatrics, Hospital Clínico Universitario de Santiago de Compostela, Santiago de Compostela, Galicia, Spain <sup>9</sup>Servicio de Microbiología y Parasitología, Complejo Hospitalario Universitario de Santiago de Compostela, Santiago de Compostela, Galicia, Spain <sup>10</sup>School of Medicine, Imperial College London, London, UK <sup>11</sup>Department of Surgery and Cancer, Imperial College London, St. Mary's Hospital, London, UK <sup>12</sup>National Heart and Lung Institute, Imperial College London, London, UK †Personalised Risk Assessment in Febrile Illness to Optimise Real-Life Management (PERFORM), London, UK. \*Co-corresponding Authors 

# Abstract

50

51

52

53

54

55

56

57

58

59

60

61

62

63

64

65

66

67

68

69

70

71

72

73

74

**Background:** The amount of SARS-CoV-2 detected in the upper respiratory tract (URT viral load) is a key driver of transmission of infection. Current evidence suggests that mechanisms constraining URT viral load are different from those controlling lower respiratory tract viral load and disease severity. Understanding such mechanisms may help to develop treatments and vaccine strategies to reduce transmission. Combining mathematical modelling of URT viral load dynamics with transcriptome analyses we aimed to identify mechanisms controlling URT viral load. Methods: COVID-19 patients were recruited in Spain during the first wave of the pandemic. RNA sequencing of peripheral blood and targeted NanoString nCounter transcriptome analysis of nasal epithelium were performed and gene expression analysed in relation to paired URT viral load samples collected within 15 days of symptom onset. Proportions of major immune cells in blood were estimated from transcriptional data using computational differential estimation. Weighted correlation network analysis (adjusted for cell proportions) and fixed transcriptional repertoire analysis were used to identify associations with URT viral load, quantified as standard deviations (z-scores) from an expected trajectory over time. **Results**: Eighty-two subjects (50% female, median age 54 years (range 3-73)) with COVID-19 were recruited. Paired URT viral load samples were available for 16 blood transcriptome samples, and 17 respiratory epithelial transcriptome samples. Natural Killer (NK) cells were the only blood cell type significantly correlated with URT viral load z-scores (r = -0.62, P = 0.010). Twenty-four blood gene expression modules were significantly correlated with URT viral load z-score, the most significant being a module of genes connected around IFNA14 (Interferon Alpha-14) expression (r = -0.60, P = 1e-10). In fixed repertoire analysis, prostanoid-related gene expression was significantly associated with higher viral load. In

nasal epithelium, only GNLY (granulysin) gene expression showed significant negative

correlation with viral load.

75

76

77

78

79

80

81

82

83

84

87

88

89

90

91

92

93

94

95

96

97

98

99

Conclusions: Correlations between the transcriptional host response and inter-individual

variations in SARS-CoV-2 URT viral load, revealed many molecular mechanisms plausibly

favouring or constraining viral load. Existing evidence corroborates many of these

mechanisms, including likely roles for NK cells, granulysin, prostanoids and interferon

alpha-14. Inhibition of prostanoid production, and administration of interferon alpha-14 may

be attractive transmission-blocking interventions.

## **Keywords**

85 COVID-19, SARS-CoV-2, upper respiratory tract, viral load, mathematical modelling,

transcriptome, gene network analysis

## **Background**

The advent of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) leading to

the coronavirus disease 2019 (COVID-19) has placed an enormous burden on affected

individuals, healthcare systems, and economies worldwide. SARS-CoV-2 is highly

transmissible and causes a wide range of severity from asymptomatic infection to severe

disease and death. The amount of SARS-CoV-2 detected in the upper respiratory tract of

infected individuals (URT viral load) is a key driver of transmission of infection (1). High

URT viral loads can increase household and non-household transmissions by up to nearly

60% and 40%, respectively (2). Interestingly, URT viral load does not necessarily correlate

with severity of illness, nor is it determined by established risk factors for poor outcome

such as age and sex (3, 4). This suggests that the host immune mechanisms involved in

constraining the virus in the URT are different from those determining the severity of

101

102

103

104

105

106

107

108

109

110

111

112

113

114

115

116

117

118

119

120

121

122

123

124

illness, although such mechanisms have not been fully elucidated. In contrast, high and persistent SARS-CoV-2 shedding in the lower respiratory tract (LRT) is associated with severe disease (5), indicating differences in the mechanisms underlying control and pathogenesis of SARS-CoV-2 in the URT and LRT. Understanding the mechanisms controlling the viral load in the URT could illuminate new strategies to prevent transmission from infected individuals and might also enable control of the localised infection before it progresses to the LRT, triggering more serious illness. URT viral load is highly dynamic. It changes over the course of illness due to dynamic interactions with the host immune response; it peaks around the time of symptom onset and then gradually decreases to a low level over the following 10 days (6, 7). Moreover, the kinetics of viral load vary between individuals, presumably determined by variation in immune responses (3). The host response constraining viral load includes both an immediate innate component and a later adaptive response (3, 8, 9). With limited in vivo data, researchers have attempted to mathematically model and explain the viral-host interaction and host immune responses to better understand the dynamics of SARS-CoV-2 viral load. We have recently developed a within-host model that has been successful in interpreting URT viral load kinetics in a wide range of data including 2172 serial measurements from 605 subjects, collected from 17 different studies (3). Despite the dynamic interaction between the virus and host immune system during SARS-CoV-2 infection and the diversity in such interaction observed between individuals, the immune response involves conserved elements which can be reflected in host transcriptomes (10). While gene expression is a dynamic process, and a single transcriptomic experiment usually captures only a "snapshot" in time, using robust transcriptional analyses we can pinpoint key biological mechanisms underlying the immune response. The host transcriptomic response in human infection is often studied in peripheral blood leukocytes.

This is because peripheral blood leukocytes mount cell-intrinsic responses to pathogens but also mount transcriptional responses to signals arising from the organs through which they circulate. Evaluating the host transcriptome in the context of the dynamics of host-pathogen interaction can be a powerful approach to elucidate mechanisms responsible for control of pathogen load (11).

Here we sought to combine mathematical modelling of URT SARS-CoV-2 viral load dynamics in individual subjects with the analysis of peripheral blood and nasal epithelium transcriptomes to identify mechanisms associated with the control of viral load. The mechanistic correlates of URT viral load identified herein may be important to develop new therapeutic and vaccine strategies to block transmission of SARS-CoV-2.

### Results

## **Participants**

We performed transcriptome analyses for 82 COVID-19 patients (50% female, median age 54 years (range 3-73 years)) recruited during the "first wave" of COVID-19 in Spain, before vaccination and natural infection became determinants of the immune response to SARS-CoV-2. Whole blood RNA sequencing (RNA-Seq) and nasal epithelium *n*Counter NanoString gene expression assay data were generated (see Methods) for 68 and 24 subjects, respectively, with 10 subjects being included in both analyses. Clinical characteristics of all subjects are provided in **Supplementary Table 1**.

The whole blood transcriptome profiles were used to construct gene co-expression networks and detect clusters of interconnected genes (see below). For gene module discovery, to optimise the generalisability of modules, we included all 68 COVID-19 subjects with RNA-Seq data (regardless of whether they had co-infections), and an additional 18 uninfected healthy control subjects and 9 subjects with non-COVID-19 infections (4 bacterial and 5

viral) (**Supplementary Table 1**), all sequenced in the same batch. However, of the COVID-19 cases who were free from suspected or proven bacterial co-infections, only 16 had URT viral load measurement and RNA samples collected on the same day and within 15 days of symptom onset (a time window during which the replicating virus can be isolated (12)). Only these 16 subjects were included in analyses correlating URT viral load with the whole blood transcriptome (**Table 1**, **Figure 1A**). Subjects were mostly female (57.1%), with ages ranging from 3 to 78 years (median = 55 years) (**Figures 1B and 1C**). The disease severity was mild (n = 3; 19%), moderate (n = 7; 44%), and severe (n = 6; 37%).

Table 1. Samples used to correlate URT viral load and whole blood transcriptome

Days of illness <sup>1</sup>	Age range (year)	Sex	Severity	Average Ct value <sup>2</sup>	Calculated viral load (log10 (viral load/ml))	Viral load z-score
3	11-15	Female	Mild	27.72	5.49	-0.32
4	51-55	Male	Moderate	37.08	2.52	-2.89
5	66-70	Male	Severe	31.53	4.34	-0.99
8	71-75	Female	Severe	35.87	5.60	0.80
8	41-45	Male	Moderate	27.41	2.91	-1.71
9	51-55	Male	Severe	35.43	3.04	-1.39
9*	51-55	Male	Moderate	32.36	3.83	-0.65
9	36-40	Female	Mild	33.1	3.98	-0.51
10	1-5	Female	Mild	21.03	3.23	-1.00
10	51-55	Female	Severe	34.39	7.45	2.94
11	71-75	Female	Moderate	29.97	4.77	0.64
11	56-60	Male	Severe	33.24	3.73	-0.33
12	41-45	Female	Moderate	36.64	2.90	-0.91
13*	51-55	Male	Severe	28.62	7.93	4
13	71-75	Male	Moderate	19.57	5.54	1.76
15	71-75	Female	Moderate	37.17	2.48	-0.69

<sup>&</sup>lt;sup>1</sup> How many days after symptom onset the viral load was measured.

We also performed a nCounter NanoString gene expression analysis on nasal epithelium samples from 24 COVID-19 patients, including 17 with URT viral load measurement within 15 days from symptom onset (**Table 2**). The subjects' ages ranged from 16 to 80 years (median = 47 years), and most had mild disease (n = 9; 53%) or severe disease (n = 6;

<sup>&</sup>lt;sup>2</sup> Cycle threshold value

<sup>\*</sup> These two samples are from the same subject

169 35.3%).

Table 2. Subjects used to correlate URT viral load with nasal epithelium NanoString profiles

Days of	Age range	Sex	Severity	Average	Calculated viral load	Viral load
illness	(year)			Ct value	(log10 (viral load/ml))	z-score
0	26-30	Female	Mild	27.53	5.94	-0.74
3	16-20	Female	Mild	27.72	5.74	-0.32
4	76-80	Female	Severe	25.36	6.46	0.56
5	66-70	Male	Severe	31.53	4.57	-0.99
6	41-45	Male	Mild	38.16	2.39	-2.8
7	46-50	Male	Mild	29.9	5.01	-0.17
8	71-75	Female	Severe	27.41	5.85	0.8
8	31-35	Female	Mild	28.93	5.33	0.33
8	31-35	Male	Mild	35.06	3.41	-1.45
9	51-55	Male	Severe	35.43	3.26	-1.39
9	36-40	Male	Mild	36.67	2.45	-2.14
10	71-75	Male	Severe	28.86	5.32	0.72
10	46-50	Female	Mild	28.78	5.48	0.87
11	26-30	Female	Mild	36.92	2.54	-1.65
12	26-30	Male	Moderate	27.97	5.61	1.4
12	61-65	Male	Severe	32.49	4.29	0.18
13	66-70	Female	Moderate	25.3	6.36	2.3

### Conversion of viral load measurements to z-scores using viral load regression model

We recently developed a regression model fitted to viral load measurements within the first 15 □ days of symptoms across 16 datasets, capturing the viral load variation during the course of infection between different individuals (3). Here, to determine whether individual subjects in the current study had higher or lower than average viral load measurements relative to their duration of illness, we used the previously published regression model to calculate a z-score for each data point representing the deviation of the data point from the mean viral load trajectory i.e. the regression line (**Tables 1 and 2, Figures 1D and 1E**; see Methods). Viral load z-scores calculated from the data were not associated with the severity of illness (**Figure 1F**). In our previous large-scale analysis of COVID-19 subjects (3), we showed that age and sex did not significantly influence URT viral load dynamics and that

URT viral load dynamics did not affect the severity of illness. Therefore, in the present study, we did not adjust the viral load z-scores for these variables.

## Exploring molecular correlates of SARS-CoV-2 viral load using whole blood

#### transcriptomics

186

187

188

189

190

191

192

193

194

195

196

197

198

199

200

201

202

203

204

205

206

207

208

209

210

We aimed to identify groups of genes for which expression correlated with viral load zscore, providing insights into the mechanisms controlling viral load. We first performed a gene signature-based deconvolution (13), as in our previous studies (11, 14). Interestingly, the computed proportion estimate of natural killer (NK) cell population was negatively correlated with viral load z-score (r = -0.62 and P = 0.010, Supplementary Figure 1). There was insufficient evidence to conclude a significant linear relationship between other leukocyte populations (B-cells, monocytes, neutrophils, CD4<sup>+</sup> T-cells, and CD8<sup>+</sup> T-cells) and viral load z-score. Gene expression counts were then adjusted for leukocyte mixture to remove the confounding effect of differences in blood leukocyte proportions between individuals. To make best use of the relatively small sample size of the selected 16 samples, we performed dimensionality reduction using weighted correlation network analysis (WGCNA) (15). First, we clustered the RNA-Seq profiles (n = 96) and removed an outlier (Supplementary Figure 2). Then, a gene co-expression network was constructed, and modules (clusters of highly co-expressed genes) were detected using the remaining 95 whole blood RNA-Seq profiles. Next, we correlated the first principal component of each module (module eigengene) to viral load z-scores in the group of 16 samples with paired data, reasoning that inducible mechanisms which restrict viral load would be enriched amongst the most strongly correlated modules. Twenty-four modules were significantly correlated with viral load (P < 0.01; Figure 2, Table 3, and Supplementary Table 2). To aid interpretation, we represented each module by its hub gene (gene with the highest

connectivity within the module). Fourteen modules were positively correlated with viral load z-score and 10 were negatively correlated (**Figure 2A**). *IFNA14* (Interferon Alpha-14) and *AIPL1* (Aryl Hydrocarbon Receptor Interacting Protein Like 1) modules showed the strongest negative correlation with viral load (r = -0.60 with P = 1e-10 and r = -0.60 with P = 2e-10, respectively). The largest positive correlation was observed for the *AC011455.2* module (r = 0.60, P = 2e-10).

**Table 3:** Modules significantly correlated with viral load z-score. Each module is represented by its hub gene. Complete lists of module genes and their information are provided in **Supplementary Table 2**.

Module	Gene count <sup>1</sup>	Genes with highest contribution to the module <sup>2</sup>
IFNA14	45	IFNA14, ADAD1, IL22, LIN28A, TMEM270
AIPL1	43	AIPL1, CFAP100, KCNK3, MOGAT2, OR5D3P, SLC13A2, SPEM1
AC011455.2	41	AC011455.2, FRMD1, TTC6, KCNK18, KIF12, SNAI2
C7orf33	36	C7orf33, DGKB, GK2, GHRH, PDZD9, SEPTIN14, SMIM40, TTLL2
IFNL3	50	IFNL3, STRA8
GALNT17	37	GALNT17, GCSAML-AS1, IP6K3, NPY, OR6B2, SIM2, SSU72P2, SSX4
CRYAA	57	CRYAA*, AC104581.2*, ACSM4*, FABP6*, GBX2*, PASD1*, PCDHA12*, PDYN*, SSMEM1*
ANGPTL7	43	ANGPTL7, CALML3, GFY, HNRNPCL2, SLC6A1, TPTE, UGT1A3
TUBB1	349	TUBB1, NRGN, SELP, MPIG6B, SPARC, GP9, PTGS1, GP6, CTTN, ABLIM3, ARHGAP6, CMTM5, GP1BB, TSPAN9, ITGB5, GUCY1B1, TREML1, PGRMC1, MYLK, ITGB3, ITGA2B, PTCRA
NAGA	638	NAGA, RASSF4, ZNF385A
NQO1	89	ABCG5*, AC003688.1*, AL121899.2*, CCL26*, DRD1*, SERPINB13*, SP5*
CHRNA4	51	CHRNA4, CPN2, EPYC, GGTLC2, HDGFL1, MARCOL, MUC21, OR1D2, OR4F15, RNASE11, SCEL, SLC35F4, XAGE2
TRIM51	32	TRIM51, AL583836.1, EPHA5, KRTAP10-7, LUZP2, TCF23
CHRDL2	31	CHRDL2, EGFLAM, OR51L1, PPFIA2, SKOR2, SLCO1B1, TM4SF4
TMPRSS7	48	AC097636.1, APOF, BPIFB2, FOXR1, MMP10, MMP12, FLG
C1QL4	42	C1QL4, DNMT3L, KRTAP10-8, OR14J1, OVOL3, PMIS2, PPP1R14D, TFAP2D, UBTFL1, H2AC18*
CYP2A7	87	CYP2A7, DCX, NGB, NR0B1, SLC17A6, SPHKAP, SPRR2D, CEACAM18, OOSP4A
AKR1C4	37	AKR1C4, RGS21, CCDC63, DSG1, GLRA1, IL20, TMEM174
AL049839.2	38	AL049839.2, CCDC190, FAM236C, FAM236D, VSNL1, MAGEB1, NRAP, RHCG
ADRA1D	54	ADRA1D, DIO3, EPHA6, H2BC1, IL31, PDE6C, SPATA31D4, TCEAL5, UNCX
ACADL	172	ACADL, AC008770.4, ADCY8, APOA4, ASZ1, BTBD16, CASQ2, CCK, CNTN1, COMP, CYP3A7, CYP4A11, DAZ1, DCAF12L1, DSG4, DUX4, DYDC2, FOXG1, FOXR2, FSHR, GRIA1, GRIA2, GRM6, IFNA13, KIF2B, KLK3, KRTAP2-2, MISP, NPY2R, NRK, NTF3, NTSR2, NXPH1, NXPH2, OR13J1, OR14A2, OR14C36, OR1C1, OR51G2, OR5L1, OR5W2, OR7A10, OR7E24, OTX2, PAX1, PAX7, PHOX2B, PRAMEF7, PRDM9, PRM3, PSG7,

		RPTN, SCYGR2, SERPINA5, SLC19A3, SLC2A7, ST8SIA3, SULT2A1, TBPL2, TRIML1, TSPY10, TSPY2, TSPY3, TSPY8, UGT1A4, ZIC1, ZSCAN5C
ZMIZ2	711	N/A <sup>3</sup>
NR3C2	208	N/A <sup>3</sup>
AL132671.2	97	AL132671.2, C2orf72, CCDC166, FGF23, MBL2, MUC3A, MYOG, SPINK6, STRA6

<sup>&</sup>lt;sup>1</sup> The number of genes involved in each module.

222

223

224

225

226

227

228

229

230

231

232

233

234

235

236

237

238

239

240

241

242

243

244

We selected the top 6 significant modules for further analysis: IFNA14, AIPL1, AC011455.2, C7orf33 (Chromosome 7 Open Reading Frame 33), IFNL3 (Interferon and GALNT17 (Polypeptide N-Acetylgalactosaminyltransferase AC011455.2, C7orf33, and GALNT17 modules were positively correlated with viral load zscore and positioned very close to each other in the hierarchical clustering (Figure 2B). Therefore, we merged their form metamodule gene sets to (AC011455.2/C7orf33/GALNT17; total gene count = 114) for further data analysis, assuming that the higher gene count would increase power to detect biologically relevant changes. We used Qiagen's Ingenuity Pathway Analysis (IPA) for biological understanding of the modules (16). Correlation coefficients between module genes and viral load z-score were used to infer the activity pattern (activation or inhibition) of the biological processes involved such as enriched pathways and upstream regulators. Figure 3A illustrates top enriched canonical pathways for the IFNA14, AIPL1, AC011455.2/C7orf33/GALNT17, and IFNL3 modules (details provided in Supplementary **Table 3**). Of these, 3 pathways showed an enrichment *P*-value of below 0.001 including 'pathogen induced cytokine storm signalling' (P = 5e-4) and 'IL-22 (Interleukin-22) signalling' (P = 8e-4) enriched in the IFNA14 module, and 'melatonin degradation' (P = 2e-4)4) enriched in the *IFNL3* module. The pathogen induced cytokine storm signalling pathway encompasses the highest number of genes from the tested module (IFNA14, IL22, CCL4 (C-

<sup>&</sup>lt;sup>2</sup> Genes with the absolute value of module membership (the correlation between the module eigengene and gene expression values) > 0.9. Genes with negative module membership are marked with an asterisk.

<sup>&</sup>lt;sup>3</sup> No genes had module membership higher than 0.9 or lower than -0.9

246

247

248

249

250

251

252

253

254

255

256

257

258

259

260

261

262

263

264

265

266

267

268

269

C Motif Chemokine Ligand 4), CD70, and COL4A4 (Collagen Type IV Alpha 4 Chain) from the IFNA14 module) compared to the other enriched pathways identified. IFNA14 and IL22, two main members of the IFNA14 module (module membership = 0.98 and P = 5e-64for both genes), are key components of the pathway. Interestingly in our dataset both genes were negatively correlated with viral load z-score (r = -0.59 and P = 3e-10 for both genes), whereas CCL4, CD70, and COL4A4 were positively correlated with viral load z-score. The IL-22 signalling pathway involves two genes, IL22 and IL22RA2 (Interleukin 22 Receptor Subunit Alpha 2), with a high contribution to the *IFNA14* module (module membership = 0.98 and 0.75 with P = 5e-64 and 1e-18, respectively) both negatively correlated with viral load z-score (r = -0.59 and -0.63 with P = 3e-10 and 7e-12, respectively). The superpathway of melatonin degradation includes three genes (CYP2F1 (Cytochrome P450 Family 2 Subfamily F Member 1), IL411 (Interleukin 4-induced gene-1), and UGT1A1 (UDP Glucuronosyltransferase Family 1 Member A1) from the IFNL3 module. However, this pathway is likely to be of less importance here as the three genes each show relatively weak individual correlations with viral load z-score (**Supplementary Table 2**). STING1 (Stimulator of Interferon Response CGAMP Interactor 1), RBP3 (Retinol Binding Protein 3), and RORC (RAR Related Orphan Receptor C) were predicted to be the most significant upstream regulators of IFNA14 module genes (P = 6e-5, 3e-4, and 4e-4, respectively) (Figures 3B and 3C). They interact with IL22, IL22RA2, CCL4, CD70, and FEZ1 (Fasciculation and Elongation Protein Zeta 1), members of the IFNA14 module which are mapped to the pathogen induced cytokine storm signalling and IL-22 signalling pathways (**Supplementary Tables 4 and 5**). None of the identified pathways and regulators showed reliable evidence of activation (absolute value of IPA activation z-score > 2) and therefore we were not able to infer an overall directionality (activation or inhibition) with respect to viral load.

We also applied the BloodGen3Module tool (17) to identify gene modules associated with

270

271

272

273

274

275

276

277

278

279

280

281

282

283

284

285

286

287

288

289

290

291

292

293

294

viral load. Unlike WGCNA which detects modules from the analysed gene expression dataset, BloodGen3Module uses fixed functionally pre-annotated modules characterising different biological responses of distinct blood cell types. We used RNA-Seq data without adjustment for leukocyte-mixture and evaluated differential expression of these modules between samples with positive and negative viral load z-scores (n = 5 and n = 11, respectively). We identified an aggregate of five modules showing high 'module response' and higher module expression in subjects with positive viral load z-score (aggregate module A34; Figure 4A and Supplementary Tables 6). A module response is defined as the percentage of genes for a given module showing significant differential expression between the groups. From the module aggregate, the Prostanoids module showed the highest module response (97%). Interestingly, we observed a significant overlap between the A34 aggregate module and TUBB1 (Tubulin Beta 1 Class VI) module which was found to be significantly positively correlated with viral load z-score by WGCNA (r = 0.39 with P = 9e-05; Figure 2). Seventy genes including *TUBB1* were common between the A34 and *TUBB1* modules (Figure 4B and Supplementary Tables 6) while A34 did not overlap with any other WGCNA module correlated with viral load z-score. Among the A34 modules, the Prostanoids module showed the highest overlap with the TUBB1 module (from 36 genes involved in the Prostanoids module, 30 were also included in the *TUBB1* module). Exploring molecular correlates of SARS-CoV-2 viral load using NanoString assay of nasal epithelium We analysed RNA isolated from nasal epithelium samples of 24 COVID-19 patients using a NanoString panel of 579 genes involved in core pathways and processes of human immune responses (Supplementary Table 7). Seventeen subjects also had paired URT viral load

measurement within 15 days from symptom onset and had no evidence of bacterial coinfection. Using WGCNA we identified seven gene co-expression networks which we refer
to as "pseudo-modules" since they were detected using a relatively low number of genes
included in the NanoString panel (**Supplementary Table 8**). Only one pseudo-module was
correlated with viral load z-score at significance threshold of 0.05 (PTK2 (Protein Tyrosine
Kinase 2) module; P = 0.016). Additionally, correlation analysis between individual gene
expression and viral load z-score detected significant correlation (absolute correlation
coefficient > 0.5 and P < 0.05; **Figure 5**) in 12 individual genes, 11 of which were
positively correlated and one (GNLY (Granulysin)) was negatively correlated.

### **Discussion**

Understanding mechanisms controlling SARS-CoV-2 viral load in the URT can provide valuable leads towards treatment and vaccine strategies aimed at reducing viral transmission. Such strategies have recently been highlighted as potential "game changers" as societies adapt to living with COVID-19 (18). Current evidence suggests that the mechanisms controlling URT viral load may be different from those controlling LRT viral load and disease severity (3-5). However, our current knowledge concerning control of URT viral load is far from complete. To unravel the biological complexity underlying the control of SARS-CoV-2 viral load, we sought to identify correlates of the variation in viral load which occurs in naturally infected individuals. Of note, we used samples from the first wave of infection in Europe, prior to vaccination, infection-induced immunity, and circulation of important variants of SARS-CoV-2. To account for the dynamic nature of URT viral load, which rapidly increases to a peak just before symptom onset and then declines more slowly, we quantified viral loads by their standardised deviation (z-scores) from a previously-derived average trajectory (3). We correlated viral load z-scores with paired peripheral

321

322

323

324

325

326

327

328

329

330

331

332

333

334

335

336

337

338

339

340

341

342

343

344

blood and nasal epithelium transcriptomes. After excluding individuals with proven or suspected bacterial co-infection and URT SARS-CoV-2 viral load samples taken more than 15 days after symptom onset, relatively small numbers of subjects for blood and nasal transcriptome analysis (n = 16 and n = 17, respectively) remained. This prompted the use of gene modules rather than individual genes for our primary analysis. This would reduce the complexity of large gene networks into relevant modules and increase the statistical power to detect those correlating with viral load. An individual module compromises genes that are more densely connected than expected by chance and often involved in the same biological functions (19). We applied two different methods to detect gene clusters, WGCNA and BloodGen3Module. The first identifies modules directly from the gene expression data and the later uses pre-annotated modules. The peripheral blood module most significantly associated with URT viral load, had IFNA14 as its hub gene. IFNA14 encodes the type I interferon, interferon α14. Interferons are glycoprotein cytokines made and released by host lymphocytes and considered to be key effectors in antiviral responses. However, their pattern of expression and function during SARS-CoV-2 infection is controversial. While some studies suggest protective effects of interferons in severe COVID-19 (20-22), others indicate poor clinical outcomes in those with increased production of interferons (23-26). There is limited data available on the correlation between SARS-CoV-2 viral load and interferon expression. Sposito et al. evaluated nasopharyngeal swabs of COVID-19 patients and showed that the expression of type I and III interferons was significantly associated with viral load in patients under 70 years old (26). However, those aged over 70 years showed no association and/or showed a significantly lower correlation coefficient. This evaluation did not include IFNA14. Also, it appears that their viral load measurements were not adjusted for the time between sample

346

347

348

349

350

351

352

353

354

355

356

357

358

359

360

361

362

363

364

365

366

367

368

369

collection and symptom onset. IFNA14 has been shown to activate a potent antiviral response via binding to IFNAR1 and IFNAR2 (Interferon Alpha and Beta Receptor Subunits 1 and 2) receptors (27, 28). This triggers the activation of JAK/STAT (Janus Kinase/Signal Transducer and Activator of Transcription) signalling complexes which subsequently induces the expression of ISGs (interferon-stimulated genes) that inhibit virus infection (29). The strong negative correlation between the IFNA14 module as well as IFNA14 as an individual gene and viral load in our data suggests that IFNA14 signalling could play a key role in controlling SARS-CoV-2 viral load, i.e. increased expression of IFNA14 restricts viral replication. Schuhenn et al. recently showed that IFNA14 is one of the most potent interferon alpha subtypes inhibiting SARS-CoV-2 replication and can cause a significant reduction of SARS-CoV-2 viral titre by up to 10<sup>5</sup>-fold (30). Furthermore, unpublished data suggest that, compared to IFNA2 (Interferon Alpha-2), which was used to treat COVID-19 patients in an uncontrolled exploratory study in China (31), IFNA14 is more efficient at preventing the infection while less detrimental to the immune system (32). Not only is IFNA14 important as an individual gene, but it also represents a network of highly connected genes in our data, the IFNA14 module, which showed a high enrichment of two canonical pathways 'pathogen induced cytokine storm signalling' and 'IL-22 signalling'. Although SARS-CoV-2 can trigger a 'cytokine storm' (33, 34), the changes in expression of genes in this pathway were not consistently associated with activation or inhibition of the pathway, agreeing with previous findings that ability to control of URT viral load is dissociated from severity of illness (3, 4). IL-22 is a cytokine released by several immune cells such as Th22 (T helper cells type 22) and plays an important role at mucosal barriers, orchestrating the interaction between the epithelial cell layer and local immune system in response to infections (35). IL-22 stimulates the IL-22 receptor complex on epithelial cells resulting in downstream activation of JAK-STAT signalling pathway

371

372

373

374

375

376

377

378

379

380

381

382

383

384

385

386

387

388

389

390

391

392

393

394

which induces multiple antiviral responses and therefore can be protective during SARS-CoV-2 infection (35-37). Elevated levels of IL-22 in the plasma have been implicated as a hallmark of severe COVID-19 (24). Taken together there is compelling evidence that the genes in the IFNA14 module act to reduce URT viral load, and add to the evidence that interferon α14 should be considered as a candidate treatment to reduce viral load in the URT and decrease transmissibility of SARS-CoV-2. The AIPL1 module was the second top module negatively corelated with viral load z-score. Unlike IFNA14, AIPL1 is not known to be involved with the pathogenesis of COVID-19, and the enriched pathways for this module contained relatively few genes. Nevertheless, enrichment of the 'α-tocopherol degradation' pathway suggests a potential role of αtocopherol (also known as Vitamin E) in the control of viral load. α-tocopherol is an antioxidant which may enhance the function of innate and adaptive immune cells, for example increasing NK cell activity and the phagocytic capacity of leukocytes, which could bolster the immune response to reduce pathogen load as observed in influenza (38, 39). Emerging evidence suggests that water soluble derivatives of  $\alpha$ -tocopherol have a potent antiviral response especially when they are used synergistically with remdesivir to inhibit SARS-CoV-2 RNA-dependent RNA polymerase (40). We also identified modules positively correlated with viral load, possibly indicating that these modules are induced in response to increasing amounts of virus or that expression of these genes favour an increase in viral replication. The most significant of these modules was the IFNL3 module. The hub gene, IFNL3, encodes a type III interferon which is a cytokine activated in response to mucosal viral infections and signals through the heterodimeric IFNLR (Interferon Lambda Receptor) that is expressed distinctly in the URT epithelial cells. This stimulates the activation of several transcription factors which upregulate ISGs. Type III interferon signalling pathway is considered slower and induces a

396

397

398

399

400

401

402

403

404

405

406

407

408

409

410

411

412

413

414

415

416

417

418

419

weaker ISG response than type 1 interferons (41, 42). The most significant upstream regulator of the *IFNL3* module is TLR9 (Toll Like Receptor 9), which may be stimulated by unmethylated CpG (Cytosine-phosphate-Guanine) sequences during SARS-CoV-2 infection (43) and result in the observed upregulation of *IFNL3* module genes. Using BloodGen3Module, we identified a cluster of blood pre-annotated transcriptional modules (A34) positively correlated with viral load. This was particularly interesting as these modules showed a significant overlap with the TUBB1 module found to be significantly positively correlated with viral load by WGCNA. From the A34 modules, the Prostanoids module showed the highest module response and overlap with the TUBB1 module. Prostanoids are a subclass of eicosanoids and regulate the inflammatory response (44). The observed association between the prostanoids module expression and viral load zscore suggests that high levels of prostanoids may supress processes which constrain viral load and therefore promote high viral load levels. This is supported by a recent study showing that abrogation of eicosanoid signalling reduces viral load and rescues mice from fatal SARS-CoV-2 infection (45). In addition to peripheral blood samples, we studied samples taken from the primary infection site, the nasal epithelium. Both blood and nasal transcriptomes can reflect the host immune response to the infection. In a respiratory infection, epithelial cells are directly infected, and peripheral blood leukocytes also respond to signals arising from the site of infection (46). However, the difference in the transcriptomic analysis approach we used for each dataset (RNAseq for peripheral blood and NanoString assay for nasal samples) made it difficult to compare the results directly. The NanoString assay analysed a relatively small number of genes (579 genes involved in immune response) and therefore the data did not yield reliable module level results. However, individual genes correlated with URT viral load z-score were identified that may be of interest. GNLY was the only negatively

correlated gene representing a likely role in the control of viral load. It is produced by a variety of killer cells such as cytotoxic T lymphocytes and NK cells, and it has both cytolytic and proinflammatory activity (47). Indeed, the expression of *GNLY* in lymphocytes has been reported to be associated with recovery in COVID-19 suggesting it may play a major role in clearance of infected cells and termination of infection (48). In agreement with the correlation between *GNLY* and viral load, we also showed that cell proportion estimates of NK cells in peripheral blood were negatively correlated with viral load z-score, highlighting the importance of this cell population in constraining the virus. For example, Witkowski et al. showed COVID-19 patients with normal NK cell numbers demonstrated a more rapid decline of viral load compared to those with low NK cell numbers (49).

Our study was limited by the relatively small sample size which may have reduced the statistical power and resulted in missed opportunities to capture some biological signals. Additionally, we cannot establish from this data whether the molecular mechanisms identified are cause or consequence of the viral load, although there are plausible mechanisms which suggest causal roles in some cases.

## **Conclusions**

To our knowledge, this is the most comprehensive study focusing on identifying molecular correlates of the SARS-CoV-2 viral load control in the URT. We identified numerous molecular processes which may contribute to the control of URT viral load. These candidate mechanisms can be the focus of further functional studies and may lead to new strategies to prevent COVID-19 and reduce SARS-CoV-2 transmission.

#### Methods

#### Study design and participants

We studied 82 COVID-19 patients recruited through the GEN-COVID study (www.gencovid.eu), a multi-center and prospective cohort designed to evaluate the effect of genetic factors on SARS-CoV-2 infection. Subjects were recruited at Hospital Clínico Universitario de Santiago de Compostela (Galicia, Spain) between March 2020 and May 2020, during the first wave of infections in Spain, before significant levels of infection- and vaccine-induced immunity in the community. COVID-19 was defined according to the Spanish national guidelines (https://www.mscbs.gob.es/profesionales/saludPublica/ccayes/alertasActual/nCov/document os.htm). The severity of the disease was defined as mild, moderate, and severe based on WHO scoring for COVID-19 patients and as described previously (50, 51). We also included 18 uninfected controls, and 9 subjects with non-COVID-19 infections recruited through the PERFORM Consortium.

#### Sample collection

445

446

447

448

449

450

451

452

453

454

455

456

457

458

459

467

468

469

- Blood samples and nasal epithelium specimens were collected at the same time at hospital
- 460 for moderate and severe COVID-19 subjects and at home for subjects with mild disease.
- Whole blood was collected into PAXgene blood RNA tubes (PreAnalytiX) and nasal
- epithelium samples were collected in Oragene CP-190 kit (DNA Genotek). Samples were
- processed as described previously (51, 52).
- One COVID-19 subject contributed two paired sets of samples (viral load and blood RNA-
- 465 Seq; Table 1) collected 3 days apart. We included both as they showed a noticeable
- difference in viral load z-score and hence were informative.

#### RNA isolation

Total RNA was isolated from blood and nasal epithelium samples using PAXgene blood

471

472

473

474

475

476

477

478

479

480

481

482

483

484

485

486

487

488

489

490

491

492

493

494

miRNA extraction and RNeasy microkit, respectively, according to the manufacturer's protocols (Qiagen). RNA amount and integrity were assessed using TapeStation 4200 (Agilent). RNA quality was checked based on DV200 metric to ensure that sufficient percentage (over 50%) of RNA fragments were greater than 200 nucleotides in length and also to estimate the optimal sample input for the *nCounter* NanoString analysis. Viral load measurements Viral load quantification: Nasopharyngeal samples were collected in Universal Transport Medium (UTM) tubes and assessed for the presence and viral load of SARS-CoV-2. We detected viral particles using a multiplex real-time PCR with the Allplex<sup>TM</sup>SARS-CoV-2 Assay (Seegene). Viral load values (viral copies per ml) were computed from the Ct values as described previously (3). Calculation of viral load z-scores: A regression model of the average trajectory of viral load over time and quantification of variation between individuals, using data from 16 datasets, was reported previously (3). Viral load values from the present study were compared to the regression line to assess whether a particular viral load measurement, sampled a certain number of days after symptom onset, was higher or lower than average. A 'z-score' was calculated for each data point by calculating its deviation from the mean trajectory and dividing by the standard deviation of the variation in viral load around the mean trajectory (Fig. 1D). **RNA** sequencing Paired-end sequencing was performed at The Wellcome Centre for Human Genetics in Oxford, UK as described previously (51). Sequencing was carried out using Novaseq6000 platform providing 150 bp paired end reads.

496

497

498

499

500

501

502

503

504

505

506

507

508

509

510

511

512

513

514

515

516

517

518

519

**RNA-Seq upstream analyses:** Adapter trimming and quality control of sequencing reads were performed with Trimmomatic version 0.36 and FastQC version 0.11.7, respectively (53, 54). The reads were then mapped against hg38 reference genome using STAR version 2.7.1a (55). RSEM version 1.3.1 was used for transcript quantification (56). Next, we performed a gene signature-based deconvolution using CellCODE as in our previous work and adjusted gene expression for leukocyte (B cells, monocytes, neutrophils, NK cells, CD4<sup>+</sup> T cells, and CD8<sup>+</sup> T cells) mixture (11, 13, 14). NanoString experiment NanoString *n*Counter assay We analysed immunological gene expression profiles of nasal epithelium using the SPRINT nCounter system (NanoString Technologies) with the Human Immunology V2 Panel (579 genes covering the core pathways and processes of the immune response, and 15 internal reference genes for data normalization). The detail of the assay is described previously (52). Differential gene expression analysis The gene expression counts adjusted for leukocyte mixture were correlated with viral load zscores using edgeR (57). Weighted correlation network analysis Gene counts were normalised using variance stabilizing transformation (VST) function of DESeq2 R package (58) and adjusted for leukocyte mixture using removeBatchEffect function of limma R package (59). We used WGCNA version 1.71 R package for weighted

correlation network analysis (15).

#### Module repertoire analysis

We applied BloodGen3Module version 1.4.0 R package (17) to the normalised gene expression counts unadjusted for cell-mixture from 16 samples with paired viral load, collected in the absence of bacterial co-infection. The package encompasses 382 functionally annotated blood transcriptional modules which have been grouped into 38 "aggregates" (A1-A38). The differential expression of the modules was compared between two groups with positive and negative viral load z-scores (n = 5 and n = 11, respectively) using t-test with fold change and p-value cut-off of 0.5 and 0.05, respectively. For each module, we computed 'module response' as the percentage of genes for the module showing significant differential expression between the two groups.

#### Further statistical analysis

The normality of distributions was assessed using the Shapiro-Wilk normality test. Pearson correlation was used to analyse the degree of association between two continuous variables. An independent-samples t-test and one-way ANOVA with Tukey's post hoc test were used to compare continuous variables between two and multiple groups, respectively.

### Figure Legends

**Figure 1**. Overview of peripheral blood gene expression and viral load in subjects with COVID-19. A) PCA (principal component analysis) plot of peripheral blood gene expression determined by RNA-Seq. Samples with paired URT viral load measurement are coloured as blue. B) and C) PCA plots represent samples with paired RNA-Seq and viral load data coloured by age and sex, respectively. D) Calculation of viral load z-scores. In the

546

547

548

549

550

551

552

553

554

555

556

557

558

559

560

561

562

563

564

565

566

567

568

569

upper panel, the viral load data of the present study (black circles) are plotted against the time since symptom onset. The green line indicates a linear regression model fitted to the viral load data from 16 different datasets previously studied. The shaded green area represents the 95% confidence interval for the regression model. As shown in the lower panel, for each data point, a z-score is calculated as the distance of the data point from the mean trajectory (green line). E) PCA plot of samples with paired data coloured based on viral load z-score. F) Viral load z-score is compared between groups of different COVID-19 severity. Red dots and whiskers represent mean and 1 standard deviation. **Figure 2.** Peripheral blood gene expression modules correlated with viral load z-score. A) For each module, the Pearson correlation with viral load z-score and corresponding p-value are displayed. The Pearson correlation scale is depicted on the right. B and C) Module network and relationship with viral load z-score. The hierarchical clustering dendrogram of the module eigengenes (B) was generated using all genes in the modules and shows the dissimilarity of eigengenes with the distance measure being one minus correlation. Modules coloured in red and blue are, respectively, positively and negatively correlated with viral load. The heatmap (C) represents module eigengene adjacency calculated as (1 + correlation)/2. **Figure 3.** Ingenuity pathway analyses of peripheral blood gene expression modules most strongly correlated with viral load. A) For each module, the top 5 significant pathways are illustrated in descending order of statistical significance as indicated by colour. For each pathway, the size of the corresponding circle represents the number of module genes that map to the pathway. The x-axis shows the ratio of the number of genes common between the corresponding module and pathway divided by the total number of genes that map to the same pathway. B) and C) For each module, the 5 most significant upstream (B) and master regulators (C) are illustrated in descending order of statistical significance as indicated by

571

572

573

574

575

576

577

578

579

580

581

582

583

584

585

586

587

588

589

590

591

592

593

594

CCL4: C-C Motif Chemokine Ligand 4

colour. For each regulator, the size of the corresponding circle represents the number of module genes downstream to the regulator. The x-axis shows the ratio of the number of module genes downstream to the corresponding regulator divided by the total number of module genes. **Figure 4.** Pre-annotated blood gene expression modules associated with viral load. A) Module fingerprint grid plot. The differential expression of the modules is compared between two groups with positive and negative viral load z-score using t-test with fold change and p-value cut-off of 0.5 and 0.05, respectively. Each block corresponds to a module position. Each row represents a 'module aggregate' including modules with the same pattern of differential expression across reference datasets. Red and blue spots represent modules with increased and decreased abundance in the positive vs negative viral load z-score group, respectively. The gradient represents 'module response' which is the percentage of genes for a given module showing significant change in abundance between the two groups. Only modules with at least 15% response have been shown. B) Overlap of genes between A34 and TUBB1 module. **Figure 5.** Correlation between nasal epithelium transcriptome and viral load z-score. The volcano plot illustrates correlation coefficients and corresponding p-values. Each dot represents a gene included in the NanoString panel. Genes strongly correlated with viral load z-score (absolute correlation coefficient > 0.5 and P < 0.05) are coloured as red (positive correlation) and blue (negative correlation). List of abbreviations AIPL1: Aryl Hydrocarbon Receptor Interacting Protein Like 1 C7orf33: Chromosome 7 Open Reading Frame 33

- 595 COL4A4: Collagen Type IV Alpha 4 Chain
- 596 COVID-19: coronavirus disease
- 597 CpG: Cytosine-phosphate-Guanine
- 598 Ct value: cycle threshold value
- 599 CYP2F1: Cytochrome P450 Family 2 Subfamily F Member 1
- 600 FEZ1: Fasciculation and Elongation Protein Zeta 1
- 601 GALNT17: Polypeptide N-Acetylgalactosaminyltransferase 17
- 602 GNLY: Granulysin
- 603 IFNA14: Interferon Alpha 14
- 604 IFNA2: Interferon Alpha-2
- 605 IFNAR1 and IFNAR2: Interferon Alpha and Beta Receptor Subunits 1 and 2
- 606 IFNL3: Interferon Lambda 3
- 607 IFNLR: Interferon Lambda Receptor
- 608 IL-22: Interleukin-22
- 609 IL22RA2: Interleukin 22 Receptor Subunit Alpha 2
- 610 ILAI1: Interleukin 4-induced gene-1
- 611 IPA: Ingenuity Pathway Analysis
- 612 ISGs: interferon-stimulated genes
- 613 JAK/STAT: Janus Kinase/Signal Transducer and Activator of Transcription
- 614 LRT: lower respiratory tract
- 615 NK cells: natural killer cells
- 616 PCA: principal component analysis
- 617 PTK2: Protein Tyrosine Kinase 2
- 618 RBP3: Retinol Binding Protein 3
- 619 RNA-Seq: RNA sequencing

620 RORC: RAR Related Orphan Receptor C 621 SARS-CoV-2: Severe Acute Respiratory Syndrome Coronavirus 2 622 STING1: Stimulator of Interferon Response CGAMP Interactor 1 623 Th22: T helper cells type 22 624 TLR9: Toll Like Receptor 9 625 TUBB1: Tubulin Beta 1 Class VI 626 UGT1A1: UDP Glucuronosyltransferase Family 1 Member A1 627 URT: upper respiratory tract 628 VL: viral load 629 WGCNA: weighted correlation network analysis 630 **Declarations** 631 632 Ethics approval and consent to participate 633 The GEN-COVID and PERFORM (Personalised Risk assessment in Febrile illness to 634 Optimise Real-life Management across the European Union; perform2020.org/) studies were 635 conducted according to the guidelines of the Declaration of Helsinki and approved by the 636 Ethics Committee of Galicia (CEIC, ref 2020/178, 18/03/2020) and St Mary's Research 637 Ethics Committee (16/LO/1684, 25/02/2013), respectively. A written informed consent was 638 obtained for each participant. If this was not done at the time of sampling, a retrospective 639 consent was sought at the earliest appropriate opportunity. 640 Here, we have replaced sample and subject IDs with identifiers that cannot reveal the 641 identity of the study subjects. 642 643 **Consent for publication** 644 Not applicable

646

647

648

649

650

651

652

653

654

655

656

657

658

659

660

661

662

663

664

665

666

667

668

669

Availability of data and materials Raw RNA-Seq data and corresponding metadata are available on ArrayExpress under the accession E-MTAB-12791. NanoString nCounter data and corresponding metadata are available at https://github.com/MahdiMoradiMarjaneh/COVID19 viral load. Codes used in the analyses can be accessed on the same GitHub repository. **Competing interests** The authors declare that they have no competing interests. Funding This work was supported by UKRI (MRC) and the DHSC (NIHR) (Grant Ref: MR/V027409/1). This study also received support from Instituto de Salud Carlos III ([ISCIII] TRINEO: PI22/00162; DIAVIR: DTS19/00049; Resvi-Omics: PI19/01039 [AS]; ReSVinext: PI16/01569 [F.M.-T.]; Enterogen: PI19/01090 [F.M.-T.]; OMI-COVI-VAC (PI22/00406 [F.M.-T.] cofinanciados FEDER), GAIN: Grupos con Potencial de Crecimiento (IN607B 2020/08, [A.S.]); ACIS: BI-BACVIR (PRIS-3, [A.S.]), and CovidPhy (SA 304 C, [A.S.]); and consorcio Centro de Investigación Biomédica en Red de Enfermedades Respiratorias (CB21/06/00103; F.M.-T.); GEN-COVID (IN845D 2020/23, F.M.-T.) and Grupos de Referencia Competitiva (IIN607A2021/05, F.M.-T.). The funders were not involved in the study design, collection, analysis, interpretation of data, the writing of this article or the decision to submit it for publication. M.M. is supported in part by the NIHR Biomedical Research Centre of Imperial College NHS Trust. JD.C. and L.C.O. acknowledge funding from the MRC Centre for Global Infectious Disease

- Analysis (reference MR/R015600/1), jointly funded by the UK Medical Research Council
- 671 (MRC) and the UK Foreign, Commonwealth & Development Office (FCDO), under the
- 672 MRC/FCDO Concordat agreement and is also part of the EDCTP2 programme supported by
- 673 the European Union.
- 674 F.L. is supported by an MRC clinical training fellowship [award MR/W000970/1]. F.L. and
- 675 R.T. are supported by the UK Coronavirus Immunology Consortium (UKCIC).
- 676 H.R.J. received support from the Wellcome Trust (4-year PhD programme, grant number
- 677 215214/Z/19/Z).

692

693

- 678 M.K. acknowledges support from the Wellcome Trust and the Medical Research Foundation
- 679 Grants (206508/Z/17/Z and MRF-160-0008-ELP-KAFO-C0801).
- 680 L.C.O. declares grant funding from Merck Group on an unrelated project.

#### 682 **Authors' contributions**

- 683 Conceptualization: A.J.C, J.D.C., L.C.O., R.S.T.; Data curation: M.M.M., I.R.-C., A.G.-C.,
- 684 D.H.-C., H.R.J., C.Y.F., Y.W., F.L.; Formal analysis: M.M.M., J.D.C, A.S., A.G.-C., M.K.;
- funding acquisition: A.J.C, J.D.C, L.C.O., R.S.T., M.L., M.K., F.M.-T., I.R.-C., A.G.-C.,
- 686 A.S.; Investigation: I.R.-C., A.G.-C., V.J.W., S.N., G.D'S., D.H.-C.; Methodology:
- 687 M.M.M., J.D.C., A.G.-C., A.S., H.R.J., V.J.W., D.H.-C.; Project administration: A.J.C, A.S.,
- 688 A.G.-C., F.M.-T.; Resources: A.J.C., F.M.-T., I.R.-C., A.G.-C., M.K.; Software: M.M.M,
- 689 H.R.J., D.H.-C.; Supervision: A.J.C, L.C.O., R.S.T., M.K., V.J.W., M.L., F.M.-T.;
- 690 Validation: M.M.M.; Visualisation: M.M.M.; Writing—original draft: M.M.M., A.J.C..;
- 691 Writing—review and editing: ALL.

#### Acknowledgements

The members and affiliations of the PERFORM consortium and the GEN-COVID

(www.gencovid.eu) study group are listed in the Supplementary text file.

#### References

695

696

697

- 698 1. Cornelissen L, Andre E. Understanding the drivers of transmission of SARS-CoV-2. Lancet
- 699 Infect Dis. 2021;21(5):580-1.
- 700 2. Marc A, Kerioui M, Blanquart F, Bertrand J, Mitja O, Corbacho-Monne M, et al. Quantifying
- 701 the relationship between SARS-CoV-2 viral load and infectiousness. Elife. 2021;10.
- 702 3. Challenger JD, Foo CY, Wu Y, Yan AWC, Marjaneh MM, Liew F, et al. Modelling upper
- respiratory viral load dynamics of SARS-CoV-2. BMC Med. 2022;20(1):25.
- 704 4. Knight SR, Ho A, Pius R, Buchan I, Carson G, Drake TM, et al. Risk stratification of patients
- 705 admitted to hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol:
- development and validation of the 4C Mortality Score. BMJ. 2020;370:m3339.
- 707 5. Chen PZ, Bobrovitz N, Premji ZA, Koopmans M, Fisman DN, Gu FX. SARS-CoV-2 shedding
- dynamics across the respiratory tract, sex, and disease severity for adult and pediatric COVID-19.
- 709 Elife. 2021;10.
- 710 6. Cevik M, Tate M, Lloyd O, Maraolo AE, Schafers J, Ho A. SARS-CoV-2, SARS-CoV, and MERS-
- 711 CoV viral load dynamics, duration of viral shedding, and infectiousness: a systematic review and
- 712 meta-analysis. Lancet Microbe. 2021;2(1):e13-e22.
- 713 7. Arons MM, Hatfield KM, Reddy SC, Kimball A, James A, Jacobs JR, et al. Presymptomatic
- 714 SARS-CoV-2 Infections and Transmission in a Skilled Nursing Facility. N Engl J Med.
- 715 2020;382(22):2081-90.
- 716 8. Diamond MS, Kanneganti TD. Innate immunity: the first line of defense against SARS-CoV-2.
- 717 Nat Immunol. 2022;23(2):165-76.
- 718 9. Blanco-Melo D, Nilsson-Payant BE, Liu WC, Uhl S, Hoagland D, Moller R, et al. Imbalanced
- 719 Host Response to SARS-CoV-2 Drives Development of COVID-19. Cell. 2020;181(5):1036-45 e9.
- 720 10. McClain MT, Constantine FJ, Henao R, Liu Y, Tsalik EL, Burke TW, et al. Dysregulated
- 721 transcriptional responses to SARS-CoV-2 in the periphery. Nat Commun. 2021;12(1):1079.
- 722 11. Georgiadou A, Lee HJ, Walther M, van Beek AE, Fitriani F, Wouters D, et al. Modelling
- 723 pathogen load dynamics to elucidate mechanistic determinants of host-Plasmodium falciparum
- 724 interactions. Nat Microbiol. 2019;4(9):1592-602.
- 725 12. Singanayagam A, Patel M, Charlett A, Lopez Bernal J, Saliba V, Ellis J, et al. Duration of
- 726 infectiousness and correlation with RT-PCR cycle threshold values in cases of COVID-19, England,
- 727 January to May 2020. Euro Surveill. 2020;25(32).
- 728 13. Chikina M, Zaslavsky E, Sealfon SC. CellCODE: a robust latent variable approach to
- 729 differential expression analysis for heterogeneous cell populations. Bioinformatics.
- 730 2015;31(10):1584-91.
- 731 14. Lee HJ, Georgiadou A, Walther M, Nwakanma D, Stewart LB, Levin M, et al. Integrated
- 732 pathogen load and dual transcriptome analysis of systemic host-pathogen interactions in severe
- 733 malaria. Sci Transl Med. 2018;10(447).
- The state of the s
- 735 BMC Bioinformatics. 2008;9:559.
- 736 16. Kramer A, Green J, Pollard J, Jr., Tugendreich S. Causal analysis approaches in Ingenuity
- 737 Pathway Analysis. Bioinformatics. 2014;30(4):523-30.
- 738 17. Altman MC, Rinchai D, Baldwin N, Toufig M, Whalen E, Garand M, et al. Development of a
- 739 fixed module repertoire for the analysis and interpretation of blood transcriptome data. Nat
- 740 Commun. 2021;12(1):4385.
- 741 18. Kozlov M. Could a nose spray a day keep COVID away? Nature. 2022.
- 742 19. Hartwell LH, Hopfield JJ, Leibler S, Murray AW. From molecular to modular cell biology.

- 743 Nature. 1999;402(6761 Suppl):C47-52.
- 744 20. Combes AJ, Courau T, Kuhn NF, Hu KH, Ray A, Chen WS, et al. Global absence and targeting
- of protective immune states in severe COVID-19. Nature. 2021;591(7848):124-30.
- 746 21. Pairo-Castineira E, Clohisey S, Klaric L, Bretherick AD, Rawlik K, Pasko D, et al. Genetic
- mechanisms of critical illness in COVID-19. Nature. 2021;591(7848):92-8.
- 748 22. Wang EY, Mao T, Klein J, Dai Y, Huck JD, Jaycox JR, et al. Diverse functional autoantibodies in
- 749 patients with COVID-19. Nature. 2021;595(7866):283-8.
- 750 23. Broggi A, Ghosh S, Sposito B, Spreafico R, Balzarini F, Lo Cascio A, et al. Type III interferons
- 751 disrupt the lung epithelial barrier upon viral recognition. Science. 2020;369(6504):706-12.
- 752 24. Lucas C, Wong P, Klein J, Castro TBR, Silva J, Sundaram M, et al. Longitudinal analyses reveal
- 753 immunological misfiring in severe COVID-19. Nature. 2020;584(7821):463-9.
- 754 25. Major J, Crotta S, Llorian M, McCabe TM, Gad HH, Priestnall SL, et al. Type I and III
- 755 interferons disrupt lung epithelial repair during recovery from viral infection. Science.
- 756 2020;369(6504):712-7.
- 757 26. Sposito B, Broggi A, Pandolfi L, Crotta S, Clementi N, Ferrarese R, et al. The interferon
- landscape along the respiratory tract impacts the severity of COVID-19. Cell. 2021;184(19):4953-68 e16.
- 760 27. Shim JM, Kim J, Tenson T, Min JY, Kainov DE. Influenza Virus Infection, Interferon Response,
- 761 Viral Counter-Response, and Apoptosis. Viruses. 2017;9(8).
- 762 28. Sun J, Wang J, Yuan X, Wu X, Sui T, Wu A, et al. Regulation of Early Host Immune Responses
- 763 Shapes the Pathogenicity of Avian Influenza A Virus. Front Microbiol. 2019;10:2007.
- 764 29. Hoffmann HH, Schneider WM, Rice CM. Interferons and viruses: an evolutionary arms race
- of molecular interactions. Trends Immunol. 2015;36(3):124-38.
- 766 30. Schuhenn J, Meister TL, Todt D, Bracht T, Schork K, Billaud JN, et al. Differential interferon-
- alpha subtype induced immune signatures are associated with suppression of SARS-CoV-2 infection.
- 768 Proc Natl Acad Sci U S A. 2022;119(8).
- 769 31. Zhou Q, Chen V, Shannon CP, Wei XS, Xiang X, Wang X, et al. Interferon-alpha2b Treatment
- 770 for COVID-19. Front Immunol. 2020;11:1061.
- 771 32. Ball K. Assessing the efficacy of non-canonical IFNA-subtypes as inhibitors of SARS-CoV-2
- replication: Medical Research Scotland; 2020 [Available from:
- 773 https://www.medicalresearchscotland.org.uk/awards/assessing-the-efficacy-of-non-canonical-ifna-
- 374 <u>subtypes-as-inhibitors-of-sars-cov-2-replication/.</u>
- 775 33. Ragab D, Salah Eldin H, Taeimah M, Khattab R, Salem R. The COVID-19 Cytokine Storm; What
- 776 We Know So Far. Front Immunol. 2020;11:1446.
- 777 34. Ye Q, Wang B, Mao J. The pathogenesis and treatment of the 'Cytokine Storm' in COVID-19. J
- 778 Infect. 2020;80(6):607-13.
- 779 35. Ahn D, Prince A. Participation of the IL-10RB Related Cytokines, IL-22 and IFN-lambda in
- 780 Defense of the Airway Mucosal Barrier. Front Cell Infect Microbiol. 2020;10:300.
- 781 36. Albayrak N, Orte Cano C, Karimi S, Dogahe D, Van Praet A, Godefroid A, et al. Distinct
- 782 Expression Patterns of Interleukin-22 Receptor 1 on Blood Hematopoietic Cells in SARS-CoV-2
- 783 Infection. Front Immunol. 2022;13:769839.
- 784 37. Klooster JPT, Bol-Schoenmakers M, van Summeren K, van Vliet ALW, de Haan CAM, van
- 785 Kuppeveld FJM, et al. Enterocytes, fibroblasts and myeloid cells synergize in anti-bacterial and anti-
- viral pathways with IL22 as the central cytokine. Commun Biol. 2021;4(1):631.
- 787 38. Han SN, Meydani SN. Impact of vitamin E on immune function and its clinical implications.
- 788 Expert Rev Clin Immunol. 2006;2(4):561-7.
- 789 39. Lewis ED, Meydani SN, Wu D. Regulatory role of vitamin E in the immune system and
- 790 inflammation. IUBMB Life. 2019;71(4):487-94.
- 791 40. Pacl HT, Tipper JL, Sevalkar RR, Crouse A, Crowder C, UAB Precision Medicine Institute, et al.
- 792 Water-soluble tocopherol derivatives inhibit SARS-CoV-2 RNA-dependent RNA polymerase. bioRxiv.
- 793 2021.

- 794 41. Pervolaraki K, Rastgou Talemi S, Albrecht D, Bormann F, Bamford C, Mendoza JL, et al.
- 795 Differential induction of interferon stimulated genes between type I and type III interferons is
- independent of interferon receptor abundance. PLoS Pathog. 2018;14(11):e1007420.
- 797 42. Peterson ST, Kennedy EA, Brigleb PH, Taylor GM, Urbanek K, Bricker TL, et al. Disruption of
- 798 Type III Interferon (IFN) Genes Ifnl2 and Ifnl3 Recapitulates Loss of the Type III IFN Receptor in the
- 799 Mucosal Antiviral Response. J Virol. 2019;93(22).
- 800 43. Bezemer GFG, Garssen J. TLR9 and COVID-19: A Multidisciplinary Theory of a Multifaceted
- 801 Therapeutic Target. Front Pharmacol. 2020;11:601685.
- 802 44. Schmid T, Brune B. Prostanoids and Resolution of Inflammation Beyond the Lipid-Mediator
- 803 Class Switch. Front Immunol. 2021;12:714042.
- Wong LR, Zheng J, Wilhelmsen K, Li K, Ortiz ME, Schnicker NJ, et al. Eicosanoid signalling
- 805 blockade protects middle-aged mice from severe COVID-19. Nature. 2022;605(7908):146-51.
- 806 46. Yu J, Peterson DR, Baran AM, Bhattacharya S, Wylie TN, Falsey AR, et al. Host Gene
- 807 Expression in Nose and Blood for the Diagnosis of Viral Respiratory Infection. J Infect Dis.
- 808 2019;219(7):1151-61.
- 809 47. Dotiwala F, Lieberman J. Granulysin: killer lymphocyte safeguard against microbes. Curr Opin
- 810 Immunol. 2019;60:19-29.
- 811 48. Zhang JY, Wang XM, Xing X, Xu Z, Zhang C, Song JW, et al. Single-cell landscape of
- immunological responses in patients with COVID-19. Nat Immunol. 2020;21(9):1107-18.
- 813 49. Witkowski M, Tizian C, Ferreira-Gomes M, Niemeyer D, Jones TC, Heinrich F, et al. Untimely
- TGFbeta responses in COVID-19 limit antiviral functions of NK cells. Nature. 2021;600(7888):295-301.
- 815 50. WHO. Clinical management of COVID-19: interim guidance, 27 May 2020. 2020.
- 816 51. Jackson H, Rivero Calle I, Broderick C, Habgood-Coote D, D'Souza G, Nichols S, et al.
- 817 Characterisation of the blood RNA host response underpinning severity in COVID-19 patients. Sci
- 818 Rep. 2022;12(1):12216.
- 819 52. Gomez-Carballa A, Rivero-Calle I, Pardo-Seco J, Gomez-Rial J, Rivero-Velasco C, Rodriguez-
- 820 Nunez N, et al. A multi-tissue study of immune gene expression profiling highlights the key role of
- the nasal epithelium in COVID-19 severity. Environ Res. 2022;210:112890.
- 822 53. Bolger AM, Lohse M, Usadel B. Trimmomatic: a flexible trimmer for Illumina sequence data.
- 823 Bioinformatics. 2014;30(15):2114-20.
- 824 54. Andrews S. FastQC: A Quality Control Tool for High Throughput Sequence Data 2010
- 825 [Available from: <a href="http://www.bioinformatics.babraham.ac.uk/projects/fastqc/">http://www.bioinformatics.babraham.ac.uk/projects/fastqc/</a>.
- 826 55. Dobin A, Davis CA, Schlesinger F, Drenkow J, Zaleski C, Jha S, et al. STAR: ultrafast universal
- 827 RNA-seq aligner. Bioinformatics. 2013;29(1):15-21.
- 828 56. Li B, Dewey CN. RSEM: accurate transcript quantification from RNA-Seq data with or without
- a reference genome. BMC Bioinformatics. 2011;12:323.
- 830 57. Robinson MD, McCarthy DJ, Smyth GK. edgeR: a Bioconductor package for differential
- expression analysis of digital gene expression data. Bioinformatics. 2010;26(1):139-40.
- 832 58. Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-
- 833 seq data with DESeq2. Genome Biol. 2014;15(12):550.
- 834 59. Ritchie ME, Phipson B, Wu D, Hu Y, Law CW, Shi W, et al. limma powers differential
- expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 2015;43(7):e47.















